Ameriprise’s Generate Biomedicines GENB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.29M Sell
85,567
-5,533
-6% -$85.1K ﹤0.01% 3329
2026
Q2
$1.54M Buy
91,100
+3,765
+4% +$51.3K ﹤0.01% 3213
2026
Q1
$1.09M Buy
+87,335
New +$1.07M ﹤0.01% 3257

Other funds holding GENB

Ameriprise's GENB Position: Q3 2026 in Review

Ameriprise reduced its Generate Biomedicines (GENB) stake by 6.1% in Q3 2026, selling an estimated $85.1K and leaving 85,567 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Ameriprise first reported a position in GENB in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.54M in Q2 2026. 109 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

  • Ameriprise held 85,567 shares of Generate Biomedicines worth $1.29M as of Q3 2026.
  • Ameriprise sold 5,533 Generate Biomedicines shares in Q3 2026, an estimated $85.1K.
  • Generate Biomedicines made up ﹤0.01% of Ameriprise's portfolio in Q3 2026, its #3329 holding.
  • Ameriprise first reported a position in Generate Biomedicines in Q1 2026 and has held it in 3 quarters since.
  • Ameriprise's Generate Biomedicines position peaked at $1.54M in Q2 2026.
  • 109 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on Ameriprise's 13F filing for Q3 2026, filed 16 Nov 2026.